| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.45 M CAD | -4.96 M CAD | -5.88 M CAD | -4.88 M CAD | -3.99 M CAD | -2.66 M CAD | -3.01 M CAD | -2.52 M CAD | -1.55 M CAD | -660856 CAD | -1.50 M CAD | -515817 CAD |
| Depreciation & Amortization | 51225 CAD | 42448 CAD | 145397 CAD | 102718 CAD | 111718 CAD | 112750 CAD | 60550 CAD | 2307 CAD | 1488 CAD | 619 CAD | 0 CAD | — |
| Stock-Based Compensation | 859494 CAD | 492236 CAD | 170382 CAD | 752591 CAD | 410007 CAD | — | — | — | — | 122015 CAD | 256051 CAD | 97002 CAD |
| Capital Expenditures | 24646 CAD | 43014 CAD | 33748 CAD | 49192 CAD | — | 0 CAD | 646183 CAD | — | 0 CAD | 3094 CAD | 0 CAD | — |
| Cash Flow from Investing | -243019 CAD | -188605 CAD | -169610 CAD | -180640 CAD | 193880 CAD | -26843 CAD | -769165 CAD | -155399 CAD | -9699 CAD | -20102 CAD | 684817 CAD | -76286 CAD |
| Cash Flow from Financing | 6.05 M CAD | 10.32 M CAD | 1.59 M CAD | -44600 CAD | 13.42 M CAD | 2.70 M CAD | 3.33 M CAD | 1.87 M CAD | 4.00 M CAD | 514292 CAD | 373255 CAD | 1.23 M CAD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -10.48 M CAD | -5.00 M CAD | -5.91 M CAD | -4.93 M CAD | — | -2.66 M CAD | -3.65 M CAD | — | -1.55 M CAD | -663950 CAD | -1.50 M CAD | — |
Lexaria Bioscience Corp. is a biotechnology company focused on enhancing the delivery of bioactive compounds, including cannabinoids and nicotine, through its proprietary drug delivery platform, DehydraTECH. The primary function of this platform is to improve the speed and efficiency of oral absorption of active pharmaceutical ingredients, with potential applications extending across a wide range of industries, including pharmaceuticals, nutraceuticals, consumer packaged goods, and more. Lexaria's technology aims to provide alternative product formulations that offer improved bioavailability and taste masking without altering the stimulant properties of the active compounds. By operating at the intersection of drug development and consumer health, the company plays a pivotal role in advancing innovative delivery solutions, contributing to the growing market of next-generation wellness products. Lexaria Bioscience Corp. continues to partner with organizations intent on developing products that integrate its advanced technology, seeking to capitalize on emerging markets where efficient delivery systems for bioactive substances are increasingly in demand.